{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:25:03Z","timestamp":1786998303357,"version":"build-2736575974"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ygyno.2024.10.019","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T13:38:36Z","timestamp":1729777116000},"page":"233-239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Phase II clinical trial assessing the efficacy of enzalutamide in advanced non-resectable granulosa cell ovarian tumors: The GREKO III study (GETHI2016\u201301)"],"prefix":"10.1016","volume":"191","author":[{"given":"Jesus","family":"Garc\u00eda-Donas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Redondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Santaballa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laia","family":"Garrigos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00aa. Jesus","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Lainez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Iglesias","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Fernando","family":"Cueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arantzazu","family":"Barquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana P.","family":"Grazioso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Hurtado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Sevillano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Grande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Francisco","family":"Rodriguez-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paloma","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2024.10.019_bb0005","series-title":"WHO Classification of Tumours of Female Reproductive Organs","author":"Kurman","year":"2014"},{"issue":"26","key":"10.1016\/j.ygyno.2024.10.019_bb0010","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1056\/NEJMoa0902542","article-title":"Mutation of FOXL2 in granulosa-cell tumors of the ovary","volume":"360","author":"Shah","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 4","key":"10.1016\/j.ygyno.2024.10.019_bb0015","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/annonc\/mdy001","article-title":"Non-epithelial ovarian cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Ray-Coquard","year":"2018","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2024.10.019_bb0020","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1159\/000515412","article-title":"Recurrence of adult granulosa cell tumor in the Greater Omentum 11 years after surgery","volume":"15","author":"Ohta","year":"2021","journal-title":"Case Rep. Gastroenterol."},{"issue":"27","key":"10.1016\/j.ygyno.2024.10.019_bb0025","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1200\/JCO.18.02419","article-title":"Management of rare ovarian cancer histologies","volume":"37","author":"Gershenson","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2024.10.019_bb0030","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1006\/gyno.1998.5304","article-title":"Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: a Gynecologic Oncology Group study","volume":"72","author":"Homesley","year":"1999","journal-title":"Gynecol. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2024.10.019_bb0035","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0959-8049(99)00142-2","article-title":"Cisplatin (P), vinblastine (V) and bleomycin (B) combination chemotherapy in recurrent or advanced granulosa(-theca) cell tumours of the ovary. An EORTC Gynaecological Cancer Cooperative Group study","volume":"35","author":"Pecorelli","year":"1999","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2024.10.019_bb0040","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ygyno.2015.11.027","article-title":"A phase II study of paclitaxel for the treatment of ovarian stromal tumors: an NRG Oncology\/ Gynecologic Oncology Group Study","volume":"140","author":"Burton","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2024.10.019_bb0045","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/cncr.28421","article-title":"Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: results of a phase 2 trial of the Gynecologic Oncology Group","volume":"120","author":"Brown","year":"2014","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.ygyno.2024.10.019_bb0050","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1001\/jamaoncol.2020.4574","article-title":"Effect of weekly paclitaxel with or without bevacizumab on progression-free rate among patients with relapsed ovarian sex cord-stromal tumors: The ALIENOR\/ENGOT-ov7 randomized clinical trial","volume":"6","author":"Ray-Coquard","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ygyno.2024.10.019_bb0055","first-page":"236","article-title":"GnRH (Depot-Lupron) in the treatment of refractory or persistent ovarian granulosa cell tumors (GCT)","volume":"13","author":"Fishman","year":"1994","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.10.019_bb0060","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/bjc.1992.28","article-title":"Progestagens for granulosa cell tumours of the ovary","volume":"65","author":"Isaacs","year":"1992","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2024.10.019_bb0065","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/bjc.1991.94","article-title":"Medroxyprogesterone acetate (MPA) in advanced granulosa cell tumours of the ovary \u2013 a new therapeutic approach?","volume":"63","author":"Malik","year":"1991","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2024.10.019_bb0070","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/0090-8258(89)90089-9","article-title":"Gonadotropin-releasing hormone agonist analog therapy effective in ovarian granulosa cell malignancy","volume":"35","author":"Martikainen","year":"1989","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2024.10.019_bb0075","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.ygyno.2004.10.042","article-title":"Hormonal treatment of a recurrent granulosa cell tumor of the ovary: case report and review of the literature","volume":"96","author":"Hardy","year":"2005","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2024.10.019_bb0080","first-page":"393","article-title":"Leuprolide acetate for treating refractory or persistent ovarian granulosa cell tumor","volume":"41","author":"Fishman","year":"1996","journal-title":"J. Reprod. Med."},{"issue":"3","key":"10.1016\/j.ygyno.2024.10.019_bb0085","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ygyno.2021.09.010","article-title":"Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor\/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903)","volume":"163","author":"Edmondson","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.ygyno.2024.10.019_bb0090","doi-asserted-by":"crossref","first-page":"5558","DOI":"10.1200\/jco.2014.32.15_suppl.5558","article-title":"Ketoconazole as inhibitor of the enzyme CYP17 in locally advanced or disseminated granulosa cell tumors of the ovary (the GreKo I study) (gethi 11-03)","volume":"32","author":"Garrigos","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.10.019_bb0095","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.5577","article-title":"Open label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: The Greko II study","volume":"35","author":"Garc\u00eda-Donas","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2024.10.019_bb0100","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/modpathol.2010.145","article-title":"The FOXL2 C134W mutation is characteristic of adult granulosa cell tumors of the ovary","volume":"23","author":"Jamieson","year":"2010","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2024.10.019_bb0105","doi-asserted-by":"crossref","first-page":"djw134","DOI":"10.1093\/jnci\/djw134","article-title":"Molecularly defined adult granulosa cell tumor of the ovary: the clinical phenotype","volume":"108","author":"McConechy","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"issue":"7","key":"10.1016\/j.ygyno.2024.10.019_bb0110","doi-asserted-by":"crossref","first-page":"825","DOI":"10.5858\/arpa.2011-0355-OA","article-title":"FOXL2 mutations in granulosa cell tumors occurring in males","volume":"136","author":"Lima","year":"2012","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.ygyno.2024.10.019_bb0115","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1136\/jmg.39.12.916","article-title":"Evolution and expression of FOXL2","volume":"39","author":"Cocquet","year":"2002","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ygyno.2024.10.019_bb0120","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/84781","article-title":"The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis\/ptosis\/epicanthus inversus syndrome","volume":"27","author":"Crisponi","year":"2001","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.ygyno.2024.10.019_bb0125","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/cjp2.198","article-title":"Adult-type granulosa cell tumor of the ovary: a FOXL2-centric disease","volume":"7","author":"Pilsworth","year":"2021","journal-title":"J. Pathol. Clin. Res."},{"key":"10.1016\/j.ygyno.2024.10.019_bb0130","doi-asserted-by":"crossref","first-page":"E101","DOI":"10.1152\/ajpendo.00534.2009","article-title":"LATS1 phosphorylates forkhead L2 and regulates its transcriptional activity","volume":"299","author":"Pisarska","year":"2010","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.ygyno.2024.10.019_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2019.105418","article-title":"Estrogen regulates forkhead transcription factor 2 to promote apoptosis of human ovarian granulosa-like tumor cells","volume":"194","author":"Wu","year":"2019","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.ygyno.2024.10.019_bb0140","doi-asserted-by":"crossref","first-page":"9160","DOI":"10.1158\/0008-5472.CAN-09-2669","article-title":"Adult-type granulosa cell tumors and FOXL2 mutation","volume":"69","author":"Kobel","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2024.10.019_bb0145","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1158\/0008-5472.CAN-20-0259","article-title":"Mutant FOXL2(C134W) hijacks SMAD4 and SMAD2\/3 to drive adult granulosa cell tumors","volume":"80","author":"Weis-Banke","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2024.10.019_bb0150","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.biocel.2016.01.003","article-title":"Impact of FOXL2 mutations on signaling in ovarian granulosa cell tumors","volume":"72","author":"Leung","year":"2016","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.10.019_bb0155","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12967-021-02754-0","article-title":"FOXO1 mitigates the SMAD3\/FOXL2C134W\u00a0transcriptomic effect in a model of human adult granulosa cell tumor","volume":"19","author":"Secchi","year":"2021","journal-title":"J. Transl. Med."},{"issue":"8","key":"10.1016\/j.ygyno.2024.10.019_bb0160","first-page":"3495","article-title":"Adult-type granulosa cell tumor of the ovary","volume":"12","author":"Li","year":"2022","journal-title":"Am. J. Cancer Res."},{"issue":"1","key":"10.1016\/j.ygyno.2024.10.019_bb0165","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ygyno.2014.03.573","article-title":"Hormone therapy in ovarian granulosa cell tumors: a systematic review","volume":"134","author":"van Meurs","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.10.019_bb0170","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ygyno.2021.07.024","article-title":"A phase 2 study of anastrozole in patients with oestrogen receptor and\/progesterone receptor positive recurrent\/metastatic granulosa cell tumours\/sex-cord stromal tumours of the ovary: The PARAGON\/ANZGOG 0903 trial","volume":"163","author":"Banerjee","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"23","key":"10.1016\/j.ygyno.2024.10.019_bb0175","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1056\/NEJMoa2003892","article-title":"Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer","volume":"382","author":"Sternberg","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ygyno.2024.10.019_bb0180","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"5928","key":"10.1016\/j.ygyno.2024.10.019_bb0185","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1126\/science.1168175","article-title":"Development of a second-generation antiandrogen for treatment of advanced prostate cancer","volume":"324","author":"Tran","year":"2009","journal-title":"Science."},{"issue":"5","key":"10.1016\/j.ygyno.2024.10.019_bb0190","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1210\/me.2009-0375","article-title":"FOXL2 Interacts with Steroidogenic Factor-1 (SF-1) and Represses SF-1-Induced CYP17 Transcription in Granulosa Cells","volume":"24","author":"Park","year":"2010","journal-title":"Mol. Endocrinol."},{"issue":"16","key":"10.1016\/j.ygyno.2024.10.019_bb0195","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.136773","article-title":"Ovarian granulosa cell tumor characterization identifies FOXL2 as an immunotherapeutic target","volume":"5","author":"Pierini","year":"2020","journal-title":"JCI Insight."},{"issue":"3","key":"10.1016\/j.ygyno.2024.10.019_bb0200","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s10637-020-01043-9","article-title":"The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial","volume":"39","author":"How","year":"2021","journal-title":"Investig. New Drugs"},{"issue":"3","key":"10.1016\/j.ygyno.2024.10.019_bb0205","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ygyno.2021.06.024","article-title":"Prevalence of predictive biomarkers in a large cohort of molecularly defined adult-type ovarian granulosa cell tumors","volume":"162","author":"Hillman","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2024.10.019_bb0210","doi-asserted-by":"crossref","first-page":"686","DOI":"10.3390\/cimb44020048","article-title":"Analysis of non-relapsed and relapsed adult type granulosa cell tumors suggests stable transcriptomes during tumor progression","volume":"44","author":"Andersson","year":"2022","journal-title":"Curr. Issues Mol. Biol."},{"issue":"5","key":"10.1016\/j.ygyno.2024.10.019_bb0215","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/PGP.0000000000001032","volume":"43","author":"Moh","year":"2024","journal-title":"Int. J. Gynecol. Pathol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824011697?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824011697?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T20:53:43Z","timestamp":1733864023000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825824011697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":43,"alternative-id":["S0090825824011697"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.10.019","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II clinical trial assessing the efficacy of enzalutamide in advanced non-resectable granulosa cell ovarian tumors: The GREKO III study (GETHI2016\u201301)","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}